1156 studies found for:    "Chronic myeloproliferative disorders"
Show Display Options
Rank Status Study
1 Completed Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocytosis;   Idiopathic Myelofibrosis;   Neutrophils;   Chronic Myeloproliferative Disorders
Intervention:
2 Active, not recruiting Research Study in Healthy Volunteers or Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Conditions: Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: microarray analysis;   Genetic: polyacrylamide gel electrophoresis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: western blotting;   Other: chromatography;   Other: high performance liquid chromatography;   Other: immunoenzyme technique
3 Completed Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Conditions: Myelodysplastic Syndromes;   Myeloproliferative Disorders;   Blood and Marrow Transplant (BMT);   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders (MPD)
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic cell transplant
4 Active, not recruiting INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Completed Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: decitabine;   Drug: romidepsin
6 Active, not recruiting Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
Condition: Myeloproliferative Neoplasms
Intervention: Drug: Pomalidomide
7 Completed JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Condition: Myeloproliferative Disorders
Intervention: Biological: Blood samples and buccal swabs
8 Completed Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
Conditions: Chronic Myeloproliferative Disorders;   Leukemia
Intervention: Drug: PS-341
9 Recruiting Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases
Conditions: Myeloproliferative Disorders;   Pulmonary Hypertension
Intervention: Other: Echocardiography, spiroergometry, cardiac catheterization
10 Completed Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
11 Terminated Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes
Interventions: Radiation: Total Body Irradiation;   Drug: Fludarabine;   Drug: Campath 1H
12 Unknown  Tipifarnib in Treating Patients With Myeloproliferative Disorders
Conditions: Leukemia;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: tipifarnib
13 Completed Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
14 Completed Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: thioguanine
15 Active, not recruiting A Study in Myeloproliferative Disorders
Conditions: Myeloproliferative Disorders;   Thrombocythemia, Essential;   Polycythemia Vera;   Primary Myelofibrosis
Intervention: Drug: LY2784544
16 Active, not recruiting Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasms of;   Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention: Drug: LY2784544
17 Recruiting Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasms (MPN);   Polycythemia Vera (PV);   Essential Thrombocythemia (ET);   Myelofibrosis (MF)
Intervention: Procedure: Upper gastrointestinal endoscopy and Doppler ultrasound
18 Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Conditions: Neural Tube Defects;   Anemia;   Leukemia, Myeloid;   Bone Marrow Transplant Failure;   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders
Interventions: Drug: CIK cells;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Thymoglobulin
19 Active, not recruiting Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Untreated Adult Acute Myeloid Leukemia;   Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: Biological: filgrastim;   Drug: clofarabine;   Drug: cytarabine
20 Active, not recruiting Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: tipifarnib;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years